EP Vantage
View EP Vantage's Articles BY TICKER:
ABII,
ABT,
AFFY,
ALIM,
ALIOF.PK,
ALNY,
ALTH,
ALXN,
AMGN,
ARIA,
ARQL,
ASTM,
AZN,
BAX,
BCRX,
BMTI,
BMY,
BSNRF.PK,
BSX,
CADX,
CBST,
CELG,
CEPH,
CHTP,
CORT,
COV,
CYPB,
CYTK,
DDSS,
DEPO,
DMYDF.PK,
DNDN,
ECYT,
ESALY.PK,
EW,
FOLD,
FRX,
GE,
GILD,
GSK,
GTXI,
HALO,
HEB,
IMGN,
INHX,
ISPH,
ISTA,
ITMN,
JAZZ,
JNJ,
KG,
LLY,
LMNX,
MDCO,
MDT,
MDVN,
MEDX,
MKGAF.PK,
MNKD,
MYGN,
NAVB,
NEUSF.PK,
NVS,
NYMX,
OMER,
ONXX,
OPOSF.PK,
PARD.PK,
PCYC,
PFE,
PPHM,
RHHBY.OB,
RIGL,
SCR,
SNN,
SNY,
STJ,
SVNT,
SXMDF.PK,
TEVA,
THRX,
TMO,
UCBJY.PK,
UTHR,
VPHM,
VRX,
VVUS,
WILLF.PK,
WMGI,
YMI
- A Delay in Protalix's Uplyso FDA Review Is Not a Disaster
- Kamada: Wise Strategy or Overly Ambitious?
- Roche Approaching High Stakes Avastin Breast Cancer FDA Approval Review
- Sanofi-Aventis: Rumored $20 Billion Swoop Could Be About Diversification
- Roche's Diabetes Dreams Fade as Taspo Data Deteriorates
-
A Closer Look at the Biovail - Valeant Merger
- Adolor's Pain Continues as Osteoarthritis Drugs Fail in Trial
- Genzyme's MS Therapy on the Fast Track: Competition Heats Up
- Onyx Pharma, Bayer Have Yet to Prove Utility of Cancer Drug
- Novartis: Gilenia Clears Latest Regulatory Hurdle With Ease
- Talecris Infusion Could Save or Sink Grifols
- Javelin / Hospira Relationship Sours as Writs Fly
- Examining Teva and Bayer's Generics Battle
- GTx Has to Reevaluate Options Following Prostate Cancer Drug Failure
- Anadys Bounces Back With Release of Positive Drug Data
- Generic Lipitor Highlights Divisive Canadian Healthcare Market
- Astellas Finally Joins Peers With Major Overseas Acquisition
- Merck's Ditching of Aranesp Biosimilar Highlights Follow-on-Biologics Pitfalls
- What Will NicOx Do Next Following FDA Let-Down?
- Did Transgene Jump the Gun With Novartis?
- Q1 Results, Healthcare Reforms Provide Pharma Opportunity to Downplay Expectations
- Intermune Left Gasping by FDA Rejection of Pirfenidone
- Transplant Drug Rejection Was Not What Bristol-Myers Squibb Needed
- How Concerned Should Onyx Investors Be?
- Data Blunder Dents NeuroSearch’s Reputation
- A Perfect Storm Brewing for Plasma Stocks
- FDA Leaves Acura Pharma Red-Faced on Lead Product
- Human Genome Sciences Down, But Not Out
- Potential Sale of Abraxis Could Hinge on Valuation
- Roche Picks Up Pace on ImmunoGen Antibody Drug Conjugate
- FDA's Early Verdict on Cell Therapeutics' Pixuvri Comes as No Surprise
- Sanofi-Aventis Places Large Bet on Diabetes Drug Candidate